Cassava Sciences

Cassava Sciences is a Texas-based clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of Alzheimer’s disease. Read more

Remi Barbier's photo - Chairman & CEO of Cassava Sciences

Chairman & CEO

Remi Barbier

CEO Approval Rating

87/100

Founded:

1998

Status:

PublicIndependent CompanyNASDAQSAVA

CASSAVA SCIENCES TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Janssen is Cassava Sciences's top competitor. Janssen is a Private company that was founded in Titusville, New Jersey in 1953. Janssen operates in the Pharmaceuticals industry. Janssen has 39,991 more employees vs. Cassava Sciences.

Novartis has been one of Cassava Sciences's top competitors. Novartis is headquartered in Basel, Basel-City, and was founded in 1996. Novartis is in the Pharmaceuticals field. Novartis generates ∞% the revenue of Cassava Sciences.

Biogen is perceived as one of Cassava Sciences's biggest rivals. Biogen was founded in 1978 in Cambridge, Massachusetts. Biogen competes in the Biotechnology field. Biogen generates $12.6B more revenue than Cassava Sciences.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Cortexyme a competitor of Cassava Sciences?

Cassava Sciences Quarterly and Annual Revenue

Coming soon for Cassava Sciences!

Annual Revenue

Cassava Sciences Acquisitions

No recent acquisitions found related to Cassava Sciences

Cassava Sciences Funding History

Since Cassava Sciences was founded in 1998, it has participated in 3 rounds of funding. In total Cassava Sciences has raised $203.8M. Cassava Sciences' last funding round was on May 2021 for a total of $2.7M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Grant
May 2021
$2.7M

National Institute on Aging

Private Placement
Feb 2021
$200M
-
Unattributed
Aug 2018
$1.1M
-

Since Cassava Sciences was founded in 1998, it has participated in 3 rounds of funding. In total Cassava Sciences has raised $203.8M. Cassava Sciences' last funding round was on May 2021 for a total of $2.7M

Cassava Sciences Investments

No recent investments found related to Cassava Sciences

Cassava Sciences News

March 23, 2021BioSpace

Cassava Sciences Announces Full-year 2020 Financial Results and Business Highlights

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's ... See more »
March 10, 2021Zacks

Here's Why

Cassava Sciences (SAVA) is progressing well with development of its Alzheimer's disease candidate, si... See more »
February 23, 2021Zacks

What's in Store?

Cassava Sciences (SAVA) will provide updates on its pipelinewhen it reports fourth-quarter 2020 resul... See more »
February 22, 2021Business Insider

Cassava Sciences jumps 16% on meeting with FDA paving the way for phase 3 study of Alzheimer's treatment

The biotech company is on track to move forward with a pivotal phase-three study for Simufilam, its l... See more »
February 22, 2021Benzinga

Cassava Sciences To Start Two Pivotal Trials With Simufilam In Alzheimer's

Cassava Sciences Inc (NASDAQ: SAVA) completes an End-of-Phase 2 (EOP2) meeting with the FDA for its l... See more »

Cassava Sciences Press Releases

March 8, 2021GlobeNewswire

Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference

AUSTIN, Texas, March 08, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-s... See more »
February 23, 2021GlobeNewswire

Cassava Sciences to Present at SVB Leerink Global Healthcare Conference

AUSTIN, Texas, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-st... See more »
August 24, 2020GlobeNewswire

Cassava Sciences Announces Lead Drug Candidate PTI-125 Is Assigned the Chemical Drug Name 'sumifilam' by USAN

- Sumifilam Is First of a New Class of Drugs That Target Filamin Proteins -... See more »
July 9, 2020GlobeNewswire

Cassava Sciences to Give Keynote Presentation on SavaDx at a Scientific Conference

AUSTIN, Texas, July 09, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq:SAVA), a biotechnolog... See more »
May 15, 2020LD Micro

Top-line Results from a Phase 2b Study of PTI-125 in Alzheimer's Disease Does Not Meet Primary Endpoint

Read this press release and other recent news about Cassava Sciences Inc. (SAVA) at ldmicro.com... See more »
January 28, 2020GlobeNewswire

Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimer's Disease

Top-Line Results Expected Mid-year 2020Top-Line Results Expected Mid-year 2020... See more »
December 6, 2019StreetInsider

Cassava Sciences Announces Additional Positive Phase 2a Clinical Data in Alzheimer's Disease at CTAD 2019

- New Data Shows Clinical Evidence of Target Engagement and Target Validation - Company Expects Data ... See more »

Social Media

Cassava Sciences Headquarters

7801 N. Capital of Texas Highway Suite 260

Austin, Texas78731

512-501-2444

Driving Directions »

Trending Companies

Cassava Sciences Summary

ABOUT

Overview

Cassava Sciences is a Texas-based clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of Alzheimer’s disease. Cassava Sciences was founded in 1998. Cassava Sciences' headquarters is located in...

CEO

Cassava Sciences's Chairman & CEO, Remi Barbier, currently has an approval rating of 87%. Cassava Sciences's primary competitors are Janssen, Novartis & Biogen.

Frequently Asked Questions about Cassava Sciences

  1. When was Cassava Sciences founded?

    Cassava Sciences was founded in 1998
  2. Who is Cassava Sciences's CEO?

    Cassava Sciences's CEO is Remi Barbier
  3. How much revenue does Cassava Sciences generate?

    Cassava Sciences generates $ < 1M in revenue
  4. How much funding does Cassava Sciences have?

    Cassava Sciences has historically raised $203.8M in funding
  1. Where is Cassava Sciences's headquarters?

    Cassava Sciences's headquarters is in Austin Texas, USA
  2. How many employees does Cassava Sciences have?

    Cassava Sciences has 9 employees
  3. What sector does Cassava Sciences operate in?

    Cassava Sciences is in Biotechnology, Pharmaceuticals
  4. Who are Cassava Sciences's competitors?

    Cassava Sciences's top competitors are Janssen, Novartis, Biogen